Leaving the study early · patients with schizophrenia
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
1 finding from 1 review
Satisfaction with treatment · patients with schizophrenia
1 finding from 1 review
Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
HALOPERIDOL probably leads to higher adverse effects: Movement disorders ‐ parkinsonism compared with PLACEBO (moderate certainty).
1 finding from 1 review
Global state: clinically important change in global state needing additional medication ‐ chlorpromazine · patients with schizophrenia
It is very uncertain whether α‐FLUPENTHIXOL changes global state: clinically important change in global state needing… compared with PLACEBO or β‐FLUPENTHIXOL (very low certainty).
1 finding from 1 review
Mental state and behaviour: clinically important change in general mental state and behaviour · patients with schizophrenia
1 finding from 1 review
Adverse effects/events: incidence of adverse effects/events · patients with schizophrenia
1 finding from 1 review
Hospital admissions · patients with schizophrenia
1 finding from 1 review
General functioning: Poor social functioning ‐ modified Cooper's ratings5,6 · patients with schizophrenia
It is very uncertain whether α‐FLUPENTHIXOL changes general functioning: Poor social functioning ‐ modified Cooper's… compared with PLACEBO or β‐FLUPENTHIXOL (very low certainty).
1 finding from 1 review
Satisfaction with treatment: satisfaction with care for recipients of care or careers · patients with schizophrenia
1 finding from 1 review
Economic: direct costs · patients with schizophrenia
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
H2 antagonists showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
H2 antagonists showed no clear difference in reports of nausea compared with placebo (low certainty).
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review